GI Dynamics Inc  

(Public, ASX:GID)   Watch this stock  
Find more results for GID
0.575
-0.005 (-0.86%)
Apr 24 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.57 - 0.58
52 week 0.49 - 0.98
Open 0.57
Vol / Avg. 570,947.00/407,761.00
Mkt cap 230.25M
P/E     -
Div/yield     -
EPS -0.12
Shares 400.44M
Beta     -
Inst. own     -
Apr 30, 2014
Q1 2014 GI Dynamics, Inc Earnings Conference Call - 8:00AM GMT+10 - Add to calendar
Apr 29, 2014
Q1 2014 GI Dynamics, Inc Earnings Release Add to calendar
Mar 4, 2014
GI Dynamics, Inc at Cowen Health Care Conference - Webcast
Feb 4, 2014
Q4 2013 GI Dynamics, Inc Earnings Conference Call - Webcast
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1109.98% -1577.74%
Operating margin -1125.95% -1545.72%
EBITD margin - -1526.16%
Return on average assets -67.56% -60.19%
Return on average equity -78.17% -68.36%
Employees 38 -
CDP Score - -

Address

1 Maguire Road
LEXINGTON, MA 02421
United States - Map
+1-781-3573300 (Phone)
+1-781-3573301 (Fax)

Website links

Description

GI Dynamics, Inc. is engaged in designing, developing, and marketing medical devices for non-surgical approaches to treating type 2 diabetes and obesity. The Company operates in Chile, Germany, the United Kingdom, the Netherlands and Austria.The Company�s primary product is the EndoBarrier Gastrointestinal Liner, or implant. The implant contains an anchor and a 60 cm impermeable sleeve that lines the duodenum and jejunum. The liner is made of a fluoropolymer material and contains a radiopaque marker embedded in the proximal end of the implant to aid in deployment. The materials used in the implant are stable in this environment. EndoBarrier Therapy is a non-surgical, non-pharmaceutical treatment to help people living with uncontrolled type 2 diabetes and obesity achieve rapid and reductions in blood sugar levels, as well as substantial weight loss. The primary purpose of these devices is to alter the GI function such that improvements in glucose control and weight loss occur.

Officers and directors

Stuart Allen Randle President, Chief Executive Officer, Executive Director
Age: 54
Robert W. Crane Chief Financial Officer, Company Secretary
Age: 53
Andy Levine Chief Technology Officer
Age: 54
Karl-Heinz Blohm Ph.D. Vice President - International Sales
Sherrie Coval-Goldsmith Vice President - Clinical and Regulatory Affairs
Anthony Tremaglio Senior Director of Marketing
Gerd Gottschalk Reimbursement Director
David Maggs M.D. Chief Medical Officer
Age: 47
Anthony Switzer Commercial Development - Australia
Mark C. Twyman Chief Commercial Officer